# Implementing the Medicare Drug Benefit

Robert Donnelly
Director, Medicare Drug Benefit Group
June 8, 2005



2006

JAN. 2006 PRESCRIPTION DRUG COVERAGE **BEGINS FOR THOSE WHO ENROLL** 

MAY 2004: DRUG DISCOUNT AVAILABLE AS TRANSITION STEP TO **DRUG BENEFIT** 

**AUG. 2004: PROPOSED RULES FOR** BENEFIT PUBLISHED

JAN. 2005: FINAL RULES PUBLISHED

AVAILABLE

JAN. 2005: NEW PREVENTIVE BENEFITS

**JUNE 2005: PEOPLE WITH LOW INCOMES** 

**NOV. 2005: ENROLLMENT IN PRESCRIPTION** 

CAN START APPLYING FOR EXTRA HELP WITH DRUG PLAN COSTS

DRUG BENEFIT PLANS BEGINS

AUG. 2004 - OCT. 2004:

**PUBLIC COMMENTS ON** 

PROPOSED RULES

2004

2003

DEC. 2003: MEDICARE **MODERNIZATION ACT** SIGNED INTO LAW




# Medicare Challenges

- Providing the best care for a Medicare population that has longer life expectancy
  - 87 years for 65 year old beneficiary today
  - Need medical management of chronic diseases, not just acute care
  - Need better coordination among providers
- High cost of health care for Medicare
  - Average increase of 13% per year overall
  - Medicare high utilization of care (includes prescription drugs, physicians, other providers)
- Rapid development of expensive technology and prescription drugs

## Part D Challenges

- Access— To ensure that plans are available nationwide-both Prescription Drug Plans and Medicare Advantage
- Operations—To ensure that plans provide high quality service to beneficiaries and are able to operate effectively
- Education, Outreach, and Enrollment—To ensure 42 million Medicare beneficiaries can make confident decisions on their prescription drug coverage

#### Part D Implementation Timeline




# MA and PDP Regions Announced

• On December 6, 2004, CMS announced the establishment of 26 MA regions and 34 PDP regions.


Regions designed to maximize plan participation

Regional PPOs must cover entire region

# PDP Regions



Note: Each territory is its own PDP region.



#### Publication of Final Rule

- CMS released the final rule for the Medicare Prescription Drug benefit on January 21, 2005.
- We received 7,696 items of correspondence containing comments on the August 2004 proposed rule.



- ☑ Application Conference January
- ✓ Weekly calls through June
- ☑ Bidding conference Early April
- ☐ Submitting claims data for Part D
  - ☐ July 18-20<sup>th</sup> in Baltimore
  - □ July 26-28 in Las Vegas
  - ☐ August 1-3 in Chicago
  - ☐ August 9-11 in New Orleans
- ☐ Payment and enrollment conference
  - ☐ August 29<sup>th</sup> September 2<sup>nd</sup> in Baltimore

#### Additional Guidance Released

- Application Materials
- Formulary Review Guidance
- LTC Guidance
- Transition Process Guidance
- Fiscal Solvency Standards
- Prescription Drug Event Data
- Employer waiver guidance
- Bid materials

# **Application Review**

MA Licensure General Waivers Solvency Application Review **Business Business Pharmacy Organizational Integrity** Access **Subcontracts** Compliance



### Formulary: What is a Part D Drug?

- A Part D drug <u>includes</u> any of the following if used for a medically accepted indication:
  - A drug dispensed only by prescription and approved by the FDA
  - A biological product dispensed only by a prescription, licensed under the Public Health Service Act (PHSA), and produced at establishment licensed under PHSA
  - Medical supplies associated with the injection of insulin (e.g., syringes, needles, alcohol swabs, swabs)
  - A vaccine licensed under the PHSA



### Formulary: What is a Part D Drug?

- What is <u>excluded</u> as a Part D drug?
  - Drugs for which payment "as so prescribed and dispensed or administered" to an individual is available under Parts A and B
  - -Drugs/classes of drugs which may be excluded under Medicaid, except for smoking cessation agents (excluded drugs may be paid for by Medicaid):



# Formulary: Excluded Drugs

- Agents when used for anorexia, weight loss, or weight gain;
- Agents when used for cosmetic purposes/hair growth;
- Agents when used for symptomatic relief of cough & colds;
- Prescription vitamins & mineral products (except prenatal vitamins & fluoride preparations);
- Nonprescription drugs;
- Covered outpatient drugs when manufacturer seeks to require associated tests or monitoring as a condition of sale;
- Barbiturates;
- Benzodiazepines

# Formulary Review: Rationale

- MMA requires CMS to review Part D formularies to ensure
  - beneficiaries have access to a broad range of medically appropriate drugs to treat all disease states
  - formulary design does not discriminate or substantially discourage enrollment of certain groups

# Formulary Review: A Visual Perspective

P&T Oversight **Review of Formulary Classification Systems** 

Review of Drug Lists

Review of
Benefit
Management
Tools

# Formulary Review: Approach

- Ensure the inclusion of a broad distribution of therapeutic categories and classes
- Utilize reasonable benchmarks to check that drug lists are robust
- Review tiering and utilization management strategies
- Identify potential outliers at each review step for further CMS investigation
- Obtain reasonable clinical justification when outliers appear to create access problems



# Formulary Review Checks

- Review of USP Categories and Classes
- Comparison to AHFS Categories and Classes
- Two Drugs per Category and Class
- USP Formulary Key Drug Types
- Tier Placement
- Widely Accepted Treatment Guidelines
- Therapeutic Categories or Pharmacologic Classes Requiring Uninterrupted Access
- Common Drugs for Medicare Population
- Quantity Limit Review
- Prior Authorization Review
- Step Therapy Review
- Insulin Supplies and Vaccines Review
- Long-Term Care Accessibility Review

## Bidding/Payment

- Four components of payment
  - Direct subsidy
  - Reinsurance
  - Low income cost sharing
  - Risk corridors
- Direct subsidy based on bid
- Reinsurance and low income cost sharing
  - Interim prospective payment based on bid
  - Final payment based on actual costs
- Risk corridors determined based on actual costs

#### Plan standardized bid

- Organization projects cost for standard benefit based on population assumed to enroll
- Standard benefit excludes beneficiary cost sharing, reinsurance and low-income cost-sharing subsidies
- Projected costs adjusted by the projected risk score of population to get standardized bid
- Bids will be aggregated to generate a single national average monthly bid amount

# Bid Review and Approval

- Review bids -- due June 6
- Determine reasonableness of assumptions/methods
  - Compare to appropriate benchmarks
  - Statistical analysis of bids submitted
    - Compare to national, regional, organizational bids
- Negotiate
- Bid Approval
- Audit

# Plan Marketing Materials

Dissemination of Part D plan information:

 Must be disclosed to each enrollee annually and at the time of enrollment

Disclosure upon request to any Part D eligible individual

# Marketing Guidelines

- CMS is drafting Part D marketing guidelines in two installments:
  - Installment I addresses the review and approval of marketing materials

Installment II will provide specific
 guidance on the process of marketing the
 Part D benefit

#### Contracts

 Draft contract will be out this month with at least a two week comment period

 CMS expects to complete contracting process by early September

#### 2006 Enrollment Timeline



Start of Program
Jan 1
2006


May 15 2006

Initial Enrollment Period for Part D Plans

**Application Period for Low-Income Subsidy** (Deemed - Automatically eligible)

July 1 2005

Full-benefit dual eligibles lose coverage under Medicaid for drugs that could be covered under Part D



# Dual Eligibles: Transition to Medicare Prescription Drug Coverage

Reaching Beneficiaries

Establishing Appropriate Safeguards

**Ensuring Continuity** of Coverage

Working with States

Providing Extra Help

#### **Transition Process**

• The final regulation requires plan sponsors to have a transition process for new enrollees prescribed Part D drugs not on the plan's formulary.

This applies to Part D drugs.

• CMS issued guidance on March 16, 2005.

# Long Term Care Coverage

- The Plan Sponsor's Formulary
   is The Formulary
- Plans must accommodate within a single formulary all medically necessary medications at all levels of care
- Coverage may include, not limited, to liquids that can be administered through feeding tubes, IV, or IM injections

#### LTC Guidance

- Convenient Access
  - PDPs required to accept any willing pharmacy (must meet performance requirements)
  - LTC facility can continue to contract exclusively if chooses as long as all Plan Sponsors in covered area are available
  - PDPs MUST demonstrate a network of "convenient" access



# Education, Outreach, and Enrollment *A Monumental Task*

• Educate 41 million Medicare Beneficiaries so they can make confident choices on prescription drug coverage

#### Target Populations

- General- Seniors/People with disabilities
- Low Income
- Retirees
- Medicare Advantage

#### Evidence-Based Outreach Strategy

- Targeted Strategies & Messages for Major Groups
  - Polling, Market Research
- Key Partnerships
- Communications Tools
  - Paid & Earned Media
  - Partners
  - Plans
- Metrics & Measurement
  - To County Level

## Campaigns Within the Campaign

- Financial Planners
- Pharmacies
- Plans
- Employers and Unions
- Disease Organizations
- Disability/Mental Health
- Physicians

- Asian Americans
- HIV/AIDS
- African Americans
- States
- American Indian/Alaskan Native
- Long Term Care



#### Getting the Message Out: Timeline

- Multi-Phased Message Platform
  - Initial Awareness (January–October 2005)
  - Focus on developing partnerships
  - General population enrollment (January September)
  - Low-income subsidy application (May October)

#### **Beneficiary Decision** (October–December 2005)

- Motivate, educate, and assist beneficiaries to enroll
- Low-income subsidy application continues
- General population enrollment
- Transition to Medicare coverage for beneficiaries with Medicaid

#### **Urgency** (January–June 2006)

 Target beneficiaries that have not yet enrolled in order to avoid increased premiums

#### General Messages

- Drug coverage will be available to everyone with Medicare
- Medicare will provide help with your drug costs, no matter how your drugs are paid for now
- Extra help will be available for those in need
- A choice of plans will be available
- All plans will include both brand name and generic drugs

RS FOR MEDICARE & MEDICAID SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES CENTERS FOR MEDICARE

#### Dual Eligibles: Key Messages

- You will start getting comprehensive drug coverage from Medicare (not Medicaid) beginning Jan 1, 2006
  - No premiums, deductibles, or coverage gaps, and only small co-pays
- You will get important information this summer and specific information in the Fall about this comprehensive coverage
- If you don't choose on your own by January, you will be assigned to a comprehensive Medicare plan, and you can switch to a different plan at any time
- Your plan must cover all medically necessary treatments and your plan must work with you and your doctors to make sure you keep getting all the drugs that you need





- Medicare is providing extra help for beneficiaries with limited resources
- No question: If you think you're eligible, it's worth it to get an application and apply it's comprehensive coverage
- The application, available online in July, is short and requires no additional financial records
- Look for an application in the mail from SSA coming in May or June it's important

# Implementing the Medicare Drug Benefit

Robert Donnelly
Director, Medicare Drug Benefit Group
June 8, 2005

